Skip to main
  1. Stocks
  2. Celldex Therapeutics
  3. Forecast
CLDX

Celldex Therapeutics (CLDX) Stock Forecast & Price Target

Celldex Therapeutics (CLDX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Celldex Therapeutics is supported by barzolvolimab’s compelling Phase 3 efficacy, including 42% to 46% Week 12 complete response rates that deepened to 45% to 54% at Week 24, plus strong activity in omalizumab-refractory and angioedema patients. Physicians in the survey still viewed the drug favorably, with 81% calling it somewhat or much more effective than current advanced therapies, while 89% expected to use it only after one or more prior advanced therapies, suggesting a pragmatic but durable adoption path. The safety profile appears manageable rather than disqualifying, as only two probable anaphylaxis cases occurred among more than 2,400 treated patients and 81% said neutropenia would not prevent prescribing, supporting a differentiated commercial opportunity in CSU and beyond.

Bears say

Celldex Therapeutics is exposed to substantial clinical and regulatory risk because its lead asset, barzolvolimab, is still in development for highly contested indications such as chronic spontaneous urticaria, chronic inducible urticaria, and atopic dermatitis, where patient recruitment delays could push results and approval timelines later than anticipated. The company also faces intense competition from established products and many clinical-stage agents, making it difficult to prove differentiation and gain adoption if clinicians remain committed to existing therapies. Because barzolvolimab accounts for the majority of its valuation, any weak data, regulatory pushback, or commercial execution missteps could materially impair the stock’s outlook.

Celldex Therapeutics (CLDX) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Celldex Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Celldex Therapeutics (CLDX) Analyst Forecast & Price Prediction

Get the latest Celldex Therapeutics (CLDX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Celldex Therapeutics (CLDX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Celldex Therapeutics (CLDX) Forecast

Analysts have given Celldex Therapeutics (CLDX) a Buy based on their latest research and market trends.

According to 11 analysts, Celldex Therapeutics (CLDX) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $65.09, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $65.09, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Celldex Therapeutics (CLDX)


Celldex Therapeutics (CLDX) Analyst Forecast & Price Prediction

Get the latest Celldex Therapeutics (CLDX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Celldex Therapeutics (CLDX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CLDX stock data and trends